Cervical Cancer Screening in Immunocompromised Women

Obstetrics and Gynecology Clinics of North America

Volumn 40, Issue 2, 2013, Pages 339-357

  Nguyen, Minh Ly ^a   Flowers, Lisa ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer screening; Combined antiretroviral therapy; HIV or AIDS; Solid organ transplant

Indexed keywords

ANTIRETROVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; VIRUS DNA;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CARCINOGENICITY; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYSTERECTOMY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; UTERUS BIOPSY; VAGINAL LAVAGE; VIRUS CARCINOGENESIS; WART VIRUS;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYSTERECTOMY; IMMUNOCOMPROMISED HOST; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TRANSPLANTS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84878650291     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.02.005     Document Type: Review

References (88)

1. UNAIDS Reports on the global AIDS epidemic 2012. Available at: . Accessed January 15, 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf.
2. HIV among women. Center for Diseases and Prevention-National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention. Available at: . Accessed January 15, 2013. http://www.cdc.gov/Features/WomenGirlsHIVAIDS/.
3. Anderson Jean EL, Sanghvi H, Kibwana S, et al. Cervical cancer screening and prevention for HIV-infected women in the developing world. Cancer prevention - from mechanisms to translational benefits. Available at: . Accessed January 15, 2013. http://www.jhpiego.org/files/CECAP_Mechanisms_Translation_Benefits_Ch9.pdf.
4. Frisch M., Biggar R.J., Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92(18):1500-1510.
5. Denny L. Cytological screening for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012, 26(2):189-196.
6. Clifford G., Franceschi S., Diaz M., et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3). S3/26-34.
7. Havre P.A., Yuan J., Hedrick L., et al. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995, 55(19):4420-4424.
8. Jones D.L., Thompson D.A., Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239(1):97-107.
9. Vernon S.D., Hart C.E., Reeves W.C., et al. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993, 27(2):133-145.
10. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006, 19(1):99-105.
11. Krajden M., Karunakaran K., So S., et al. Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia. Clin Vaccine Immunol 2009, 16(12):1840-1843.
12. Palefsky J.M. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999, 21(Suppl 1):S42-S48.
13. Sun X.W., Kuhn L., Ellerbrock T.V., et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337(19):1343-1349.
14. Moscicki A.B., Ellenberg J.H., Vermund S.H., et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000, 154(2):127-134.
15. Clifford G.M., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998.
16. Patel P., Hanson D.L., Sullivan P.S., et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008, 148(10):728-736.
17. Engels E.A., Biggar R.J., Hall H.I., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123(1):187-194.
18. Simard E.P., Pfeiffer R.M., Engels E.A. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011, 117(5):1089-1096.
19. Vajdic C.M., van Leeuwen M.T., McDonald S.P., et al. Increased incidence of squamous cell carcinoma of eye after kidney transplantation. J Natl Cancer Inst 2007, 99(17):1340-1342.
20. Guiguet M., Boue F., Cadranel J., et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009, 10(12):1152-1159.
21. Massad L.S., Seaberg E.C., Watts D.H., et al. Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer 2009, 115(3):524-530.
22. Abraham A.G., Strickler H.D., Jing Y., et al. Invasive cervical cancer risk among HIV-infected women: a North American multi-cohort collaboration prospective study. J Acquir Immune Defic Syndr 2013, 62(4):405-413.
23. Hampson L., Kitchener H.C., Hampson I.N. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006, 11(6):813-825.
24. Palefsky J. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges. AIDS 2012, 26(8):1035-1036.
25. Gravitt P.E., Paul P., Katki H.A., et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One 2010, 5(10):e13711.
26. Adler D.H. The impact of HAART on HPV-related cervical disease. Curr HIV Res 2010, 8(7):493-497.
27. Levine A.M., Seaberg E.C., Hessol N.A., et al. HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol 2010, 28(9):1514-1519.
28. Moloney F.J., Comber H., O'Lorcain P., et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006, 154(3):498-504.
29. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007, 15(4):130-133.
30. Moloney F.J., Kelly P.O., Kay E.W., et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004, 30(4 Pt 2):674-678.
31. Heard I., Cubie H., Mesher D., et al. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2012, 120(1):41-49.
32. Fairley C.K., Sheil A.G., McNeil J.J., et al. The risk of ano-genital malignancies in dialysis and transplant patients. Clinical Nephrology 1994, 41(2):101-105.
33. Budde K., Sommerer C., Becker T., et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010, 10(3):571-581.
34. Lillo F.B., Ferrari D., Veglia F., et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001, 184(5):547-551.
35. Paramsothy P., Jamieson D.J., Heilig C.M., et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009, 113(1):26-31.
36. Zeier M.D., Botha M.H., van der Merwe F.H., et al. Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus. J Low Genit Tract Dis 2012, 16(3):243-250.
37. Minkoff H., Zhong Y., Burk R.D., et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010, 201(5):681-690.
38. Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009, 4(1):68-73.
39. Clifford G.M., Goncalves M.A., Franceschi S., HPV and HIV Study Group Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20(18):2337-2344.
40. Massad L.S., D'Souza G., Tian F., et al. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. Obstet Gynecol 2012, 120(4):791-797.
41. Firnhaber C., Mayisela N., Mao L., et al. Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One 2013, 8(1):e53494.
42. Harris T.G., Burk R.D., Palefsky J.M., et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005, 293(12):1471-1476.
43. Ortiz A.P., Colon-Lopez V., Girona-Lozada G., et al. Report of the 2012 capacity building for HIV-HPV clinical trials recruitment among minority underserved populations of Hispanic origin in Puerto Rico. P R Health Sci J 2012, 31(3):185-187.
44. Moscicki A.B., Ellenberg J.H., Crowley-Nowick P., et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004, 190(8):1413-1421.
45. Setse R., Siberry G.K., Moss W.J., et al. Cervical pap screening cytological abnormalities among HIV-infected adolescents in the LEGACY cohort. J Pediatr Adolesc Gynecol 2012, 25(1):27-34.
46. Dantal J., Berthoux F., Moal M.C., et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010, 23(11):1084-1093.
47. Laing M.E., Moloney F.J., Kay E.W., et al. Malignant melanoma in transplant patients: review of five cases. Clin Exp Dermatol 2006, 31(5):662-664.
48. ACOG Committee on Practice Bulletins-Gynecology ACOG Practice Bulletin No. 117: gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010, 116(6):1492-1509.
49. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
50. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012, 16(3):175-204.
51. Minkoff H., Feldman J.G., Strickler H.D., et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 2004, 189(10):1821-1828.
52. Massad L.S., Xie X., Greenblatt R.M., et al. Effect of human immunodeficiency virus infection on the prevalence and incidence of vaginal intraepithelial neoplasia. Obstet Gynecol 2012, 119(3):582-589.
53. Birkeland S.A., Storm H.H., Lamm L.U., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995, 60(2):183-189.
54. Jensen P., Moller B., Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000, 42(2 Pt 1):307.
55. Buell J.F., Brock G.N. Risk of cancer in liver transplant recipients: a look into the mirror. Liver Transpl 2008, 14(11):1561-1563.
56. Jensen P., Hansen S., Moller B., et al. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone?. Transplant Proc 1999, 31(1-2):1120.
57. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986, 58(3):611-616.
58. Porreco R., Penn I., Droegemueller W., et al. Gynecologic malignancies in immunosuppressed organ homograft recipients. Obstet Gynecol 1975, 45(4):359-364.
59. Alloub M.I., Barr B.B., McLaren K.M., et al. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989, 298(6667):153-156.
60. Brown M.R., Noffsinger A., First M.R., et al. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol 2000, 79(2):220-224.
61. Busnach G., Piselli P., Arbustini E., et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006, 38(10):3533-3535.
62. Gentile G., Formelli G., Orsoni G., et al. Immunosuppression and human genital papillomavirus infection. Eur J Gynaecol Oncol 1991, 12(1):79-81.
63. Halpert R., Fruchter R.G., Sedlis A., et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986, 68(2):251-258.
64. Veroux M., Corona D., Scalia G., et al. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant Proc 2009, 41(4):1191-1194.
65. Meeuwis K.A., Melchers W.J., Bouten H., et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 2012, 93(9):914-922.
66. Pietrzak B., Mazanowska N., Ekiel A.M., et al. Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J 2012, 9:117.
67. Morrison E.A., Dole P., Sun X.W., et al. Low prevalence of human papillomavirus infection of the cervix in renal transplant recipients. Nephrol Dial Transplant 1996, 11(8):1603-1606.
68. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296(23):2823-2831.
69. Hwang J.K., Moon I.S., Kim J.I. Malignancies after kidney transplantation: a 40-year single-center experience in Korea. Transpl Int 2011, 24(7):716-721.
70. Collett D., Mumford L., Banner N.R., et al. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010, 10(8):1889-1896.
71. Kasiske B.L., Zeier M.G., Chapman J.R., et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010, 77(4):299-311.
72. EBPG Expert Group on Renal Transplantation European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 2002, 17(Suppl 4):32. 4-6.
73. Inserra P., Abrahamsen M., Papenfuss M., et al. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 2003, 14(12):800-804.
74. Dugue P.A., Rebolj M., Garred P., et al. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther 2013, 13(1):29-42.
75. Engels E.A., Pfeiffer R.M., Fraumeni J.F., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306(17):1891-1901.
76. Adami J., Gabel H., Lindelof B., et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003, 89(7):1221-1227.
77. Iuri Usêda Santana, Alline do Nascimento Gomes, Leomar D'Cirqueira Lyrio, et al. Systemic lupus erythematous, human papilomavirus infection, cervical pre-malignant and malignant lesions: a systemic review. Clinical Rheumatology 2011, 30:665-672.
78. Hemminki K., Liu X., Ji J., et al. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol 2012, 127(1):180-185.
79. Bernatsky S.R., Cooper G.S., Mill C., et al. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 2006, 33(1):45-49.
80. Tam L.S., Chan A.Y., Chan P.K., et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004, 50(11):3619-3625.
81. Klumb E.M., Pinto A.C., Jesus G.R., et al. Are women with lupus at higher risk of HPV infection?. Lupus 2010, 19(13):1485-1491.
82. Bateman H., Yazici Y., Leff L., et al. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000, 9(7):542-544.
83. Mofenson L.M., Brady M.T., Danner S.P., et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009, 58(RR-11):1-166.
84. Biggar R.J., Chaturvedi A.K., Goedert J.J., Study HACM, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007, 99(12):962-972.
85. Dal Maso L., Polesel J., Serraino D., et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009, 100(5):840-847.
86. Chaturvedi A.K., Madeleine M.M., Biggar R.J., et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101(16):1120-1130.
87. Saslow D., Solomon D., Lawson H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137(4):516-542.
88. Moyer V.A., Force USPST Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 156(12):880-891. W312.